Search

Your search keyword '"MACFARLANE, ROBYN"' showing total 31 results
Start Over Author "MACFARLANE, ROBYN"
31 results on '"MACFARLANE, ROBYN"'

3. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Author

Park, Se Hoon, van der Heijden, Michiel S., Necchi, Andrea, Castellano, Daniel, Bamias, Aristotelis, Lee, Jae Lyun, De Giorgi, Ugo, Bögemann, Martin, Eigl, Bernhard J., Tsiatas, Marinos, Powles, Thomas, Novikov, Andrey, Skoneczna, Iwona, Mukherjee, Som D., Suarez, Cristina, Westgeest, Hans, Fradet, Yves, Flechon, Aude, Ou, Yen-Chuan, Park, Inkeun, Matveev, Vsevolod, Pérez-Valderrama, Begoña, Cheng, Susanna, Frank, Stephen, Gurney, Howard, Anido, Urbano, Hamzaj, Alketa, Retz, Margitta, Sridhar, Srikala, Scagliotti, Giorgio Vittorio, Voortman, Jens, Alekseev, Boris, Alyasova, Anna, Komyakov, Boris, Dumez, Herlinde, Pavic, Michel, Kimura, Go, Mizokami, Atsushi, Osanto, Susanne, Arranz, Jose Angel, Piersma, Djura, Shin, Sang Joon, Karyakin, Oleg, Delgado, Ignacio, Gonzalez, Jose Luis, Pang, See-Tong, Tran, Anna, Lipatov, Oleg, Su, Wen-Pin, Flaig, Thomas, Alva, Ajjai, Park Kyong, Hwa, Kopyltsov, Evgeny, Almagro, Elena, Domenech, Monserrat, Chang, Yen-Hwa, Sautois, Brieuc, Ravaux, Andre, Aravantinos, Gerasimos, Georgoulias, Vasileios, Mulder, Sasja, Kim, Yu Jung, Kater, Fabio, Chevreau, Christine, Tagawa, Scott, Zalewski, Pawel, Joly, Florence, Loriot, Yohann, Hatiboglu, Gencay, Gianni, Luca, Morelli, Franco, Tambaro, Rosa, Hashimoto, Yasuhiro, Nosov, Alexander, Font, Albert, Rodriguez-Vida, Alejo M., Jones, Robert, Vasudev, Naveen, Srinivas, Sandhya, Zhang, Jingsong, Gil, Thierry, Finch, Daygen, Grimm, Marc-Oliver, Su, Yu-Li, Chowdhury, Simon, Hocking, Christopher, Plas, Eugen, North, Scott, Jensen, Niels Viggo, Theodore, Christine, Imkamp, Florian, Peer, Avivit, Kobayashi, Takashi, Sakai, Hideki, Sassa, Naoto, Yoshimura, Kazuhiro, Aarts, Maureen, Ferreira Castro, Ana, Topuzov, Marlen, Rodriguez, Juan Francisco, Vazquez, Federico Jose, Tsai, Yu-Chieh, Crabb, Simon, Hussain, Syed, Bendell, Johanna, Gross-Goupil, Marine, Gwenaelle, Gravis, Berger, Raanan, Statsenko, Galina, Evans, Linda, Drakaki, Alexandra, Somer, Bradley, Davis, Ian, Lynam, James, Borges, Giuliano, Dettino, Aldo, Fay, André P., Martins, Graziella, Zucca, Luis Eduardo, Agerbaek, Mads, Kalofonos, Haralambos, Rosenbaum, Eli, Enokida, Hideki, Kikukawa, Hiroaki, Nishimura, Kazuo, Tamada, Satoshi, Uemura, Motohide, Lopez, Yamil, Gietema, Jourik, Slojewski, Marcin, Fernandes, Isabel, Smolin, Alexey, Mazhar, Danish, Kalebasty, Arash Rezazadeh, Carthon, Bradley, Loidl, Wolfgang, Franke, Fabio, Girotto, Gustavo, Alimohamed, Nimira, Macfarlane, Robyn, Pappot, Helle, Niegisch, Guenter, Mavroudis, Dimitrios, Sella, Avishay, Porta, Camillo, Ebara, Shin, Nakamura, Motonobu, Obara, Wataru, Okuno, Norihiko, Shinohara, Nobuo, Sugimoto, Mikio, Suzuki, Akitaka, Tokuda, Noriaki, Uemura, Hiroji, Yamaguchi, Akito, Ramirez, Francisco, Rozanowski, Pawel, Wiechno, Pawel, Keam, Bhumsuk, Kislov, Nikolay, Plaksin, Denis, Cicin, Irfan, Kumar, Satish, Galsky, Matthew D., Petrylak, Daniel P., Rosales, Joseph, Vaishampayan, Ulka, Culine, Stephane, Papandreou, Christos, Nara, Taketoshi, Erman, Mustafa, Kreiger, Laurence, Janoski, Juliana, Rosa, Diogo, Siqueira, Mariana, Canil, Christina, Sengelov, Lisa, Tourani, Jean-Marc, Arai, Gaku, Hashine, Katsuyoshi, Kawakita, Mutsushi, Nakaigawa, Noboru, Nomi, Hayahito, Shiina, Hiroaki, Suzuki, Hiroyoshi, Yonese, Junji, Kuri, Roberto, Macedo, Eleazar, Rivera, Samuel, Villalobos Prieto, Alberto, Polakiewicz-Gilowska, Anna, Zaucha, Renata, Lopes, Fabio, Ponomarev, Roman, Pomerantz, Mark, Shariat, Shahrokh, Luk, Cynthia, Lesniewski-Kmak, Krzysztof, van der Heijden, Michiel S, Galsky, Matthew D, Petrylak, Daniel P, Ogawa, Osamu, Lee, Jae-Lyun, Eigl, Bernhard J, Mukherjee, Som D, Suárez, Cristina, Fay, André P, Duran, Ignacio, Wildsmith, Sophie, He, Philip, Angra, Natasha, Gupta, Ashok K, Levin, Wendy, and Bellmunt, Joaquim

Published
2020
Full Text
View/download PDF

4. A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205

Author

Hotte, Sebastien J., Chi, Kim N., Joshua, Anthony M., Tu, Donsheng, Macfarlane, Robyn J., Gregg, Rirchard W., Ruether, Joseph D., Basappa, Naveen S., Finch, Daygen, Salim, Muhammad, Winquist, Eric W., Torri, Vamsee, North, Scott, Kollmannsberger, Christian, Ellard, Susan L., Eigl, Bernard J., Tinker, Anna, Allan, Alison L., Beja, Kevin, Annala, Matti, Powers, Jean, Wyatt, Alexander W., and Seymour, Lesley

Published
2019
Full Text
View/download PDF

6. Prospective ctDNA genotyping for treatment selection in metastatic castration-resistant prostate cancer (mCRPC): The Canadian Cancer Trials Group phase II PC-BETS umbrella study.

Author

Kwan, Edmond Michael, primary, Rushton, Moira Katherine, additional, Tu, Wilson, additional, Hotte, Sebastien J., additional, Mukherjee, Som D., additional, Ong, Michael, additional, Kolinsky, Michael Paul, additional, Hamilou, Zineb, additional, Winquist, Eric, additional, Ferrario, Cristiano, additional, Macfarlane, Robyn Jane, additional, Saad, Fred, additional, Salim, Muhammad, additional, Jiang, Di Maria, additional, Tu, Dongsheng, additional, Hutchenreuther, James, additional, Annala, Matti, additional, Seymour, Lesley, additional, Chi, Kim N., additional, and Wyatt, Alexander William, additional

Published
2023
Full Text
View/download PDF

12. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Author

Powles, Thomas, primary, van der Heijden, Michiel S, additional, Castellano, Daniel, additional, Galsky, Matthew D, additional, Loriot, Yohann, additional, Petrylak, Daniel P, additional, Ogawa, Osamu, additional, Park, Se Hoon, additional, Lee, Jae-Lyun, additional, De Giorgi, Ugo, additional, Bögemann, Martin, additional, Bamias, Aristotelis, additional, Eigl, Bernhard J, additional, Gurney, Howard, additional, Mukherjee, Som D, additional, Fradet, Yves, additional, Skoneczna, Iwona, additional, Tsiatas, Marinos, additional, Novikov, Andrey, additional, Suárez, Cristina, additional, Fay, André P, additional, Duran, Ignacio, additional, Necchi, Andrea, additional, Wildsmith, Sophie, additional, He, Philip, additional, Angra, Natasha, additional, Gupta, Ashok K, additional, Levin, Wendy, additional, Bellmunt, Joaquim, additional, van der Heijden, Michiel S., additional, Lee, Jae Lyun, additional, Eigl, Bernhard J., additional, Powles, Thomas, additional, Mukherjee, Som D., additional, Suarez, Cristina, additional, Westgeest, Hans, additional, Flechon, Aude, additional, Ou, Yen-Chuan, additional, Park, Inkeun, additional, Matveev, Vsevolod, additional, Pérez-Valderrama, Begoña, additional, Cheng, Susanna, additional, Frank, Stephen, additional, Anido, Urbano, additional, Hamzaj, Alketa, additional, Retz, Margitta, additional, Sridhar, Srikala, additional, Scagliotti, Giorgio Vittorio, additional, Voortman, Jens, additional, Alekseev, Boris, additional, Alyasova, Anna, additional, Komyakov, Boris, additional, Dumez, Herlinde, additional, Pavic, Michel, additional, Kimura, Go, additional, Mizokami, Atsushi, additional, Osanto, Susanne, additional, Arranz, Jose Angel, additional, Piersma, Djura, additional, Shin, Sang Joon, additional, Karyakin, Oleg, additional, Delgado, Ignacio, additional, Gonzalez, Jose Luis, additional, Pang, See-Tong, additional, Tran, Anna, additional, Lipatov, Oleg, additional, Su, Wen-Pin, additional, Flaig, Thomas, additional, Alva, Ajjai, additional, Park Kyong, Hwa, additional, Kopyltsov, Evgeny, additional, Almagro, Elena, additional, Domenech, Monserrat, additional, Chang, Yen-Hwa, additional, Sautois, Brieuc, additional, Ravaux, Andre, additional, Aravantinos, Gerasimos, additional, Georgoulias, Vasileios, additional, Mulder, Sasja, additional, Kim, Yu Jung, additional, Kater, Fabio, additional, Chevreau, Christine, additional, Tagawa, Scott, additional, Zalewski, Pawel, additional, Joly, Florence, additional, Hatiboglu, Gencay, additional, Gianni, Luca, additional, Morelli, Franco, additional, Tambaro, Rosa, additional, Hashimoto, Yasuhiro, additional, Nosov, Alexander, additional, Font, Albert, additional, Rodriguez-Vida, Alejo M., additional, Jones, Robert, additional, Vasudev, Naveen, additional, Srinivas, Sandhya, additional, Zhang, Jingsong, additional, Gil, Thierry, additional, Finch, Daygen, additional, Grimm, Marc-Oliver, additional, Su, Yu-Li, additional, Chowdhury, Simon, additional, Hocking, Christopher, additional, Plas, Eugen, additional, North, Scott, additional, Jensen, Niels Viggo, additional, Theodore, Christine, additional, Imkamp, Florian, additional, Peer, Avivit, additional, Kobayashi, Takashi, additional, Sakai, Hideki, additional, Sassa, Naoto, additional, Yoshimura, Kazuhiro, additional, Aarts, Maureen, additional, Ferreira Castro, Ana, additional, Topuzov, Marlen, additional, Rodriguez, Juan Francisco, additional, Vazquez, Federico Jose, additional, Tsai, Yu-Chieh, additional, Crabb, Simon, additional, Hussain, Syed, additional, Bendell, Johanna, additional, Gross-Goupil, Marine, additional, Gwenaelle, Gravis, additional, Berger, Raanan, additional, Statsenko, Galina, additional, Evans, Linda, additional, Drakaki, Alexandra, additional, Somer, Bradley, additional, Davis, Ian, additional, Lynam, James, additional, Borges, Giuliano, additional, Dettino, Aldo, additional, Fay, André P., additional, Martins, Graziella, additional, Zucca, Luis Eduardo, additional, Agerbaek, Mads, additional, Kalofonos, Haralambos, additional, Rosenbaum, Eli, additional, Enokida, Hideki, additional, Kikukawa, Hiroaki, additional, Nishimura, Kazuo, additional, Tamada, Satoshi, additional, Uemura, Motohide, additional, Lopez, Yamil, additional, Gietema, Jourik, additional, Slojewski, Marcin, additional, Fernandes, Isabel, additional, Smolin, Alexey, additional, Mazhar, Danish, additional, Kalebasty, Arash Rezazadeh, additional, Carthon, Bradley, additional, Loidl, Wolfgang, additional, Franke, Fabio, additional, Girotto, Gustavo, additional, Alimohamed, Nimira, additional, Macfarlane, Robyn, additional, Pappot, Helle, additional, Niegisch, Guenter, additional, Mavroudis, Dimitrios, additional, Sella, Avishay, additional, Porta, Camillo, additional, Ebara, Shin, additional, Nakamura, Motonobu, additional, Obara, Wataru, additional, Okuno, Norihiko, additional, Shinohara, Nobuo, additional, Sugimoto, Mikio, additional, Suzuki, Akitaka, additional, Tokuda, Noriaki, additional, Uemura, Hiroji, additional, Yamaguchi, Akito, additional, Ramirez, Francisco, additional, Rozanowski, Pawel, additional, Wiechno, Pawel, additional, Keam, Bhumsuk, additional, Kislov, Nikolay, additional, Plaksin, Denis, additional, Cicin, Irfan, additional, Kumar, Satish, additional, Galsky, Matthew D., additional, Petrylak, Daniel P., additional, Rosales, Joseph, additional, Vaishampayan, Ulka, additional, Culine, Stephane, additional, Papandreou, Christos, additional, Nara, Taketoshi, additional, Erman, Mustafa, additional, Kreiger, Laurence, additional, Janoski, Juliana, additional, Rosa, Diogo, additional, Siqueira, Mariana, additional, Canil, Christina, additional, Sengelov, Lisa, additional, Tourani, Jean-Marc, additional, Arai, Gaku, additional, Hashine, Katsuyoshi, additional, Kawakita, Mutsushi, additional, Nakaigawa, Noboru, additional, Nomi, Hayahito, additional, Shiina, Hiroaki, additional, Suzuki, Hiroyoshi, additional, Yonese, Junji, additional, Kuri, Roberto, additional, Macedo, Eleazar, additional, Rivera, Samuel, additional, Villalobos Prieto, Alberto, additional, Polakiewicz-Gilowska, Anna, additional, Zaucha, Renata, additional, Lopes, Fabio, additional, Ponomarev, Roman, additional, Pomerantz, Mark, additional, Shariat, Shahrokh, additional, Luk, Cynthia, additional, and Lesniewski-Kmak, Krzysztof, additional

Published
2020
Full Text
View/download PDF

16. Prostate cancer biomarker enrichment and treatment selection (PC-BETS) study: A Canadian cancer trials group phase II umbrella trial for metastatic castration-resistant prostate cancer (mCRPC).

Author

Chi, Kim N., primary, Mukherjee, Som, additional, Saad, Fred, additional, Winquist, Eric, additional, Ong, Michael, additional, Kolinsky, Michael Paul, additional, Sacher, Adrian G., additional, Ferrario, Cristiano, additional, Salim, Muhammad, additional, Macfarlane, Robyn Jane, additional, Iqbal, Nayyer, additional, Hotte, Sebastien J., additional, Annala, Matti, additional, Petrovic, Jelena, additional, Tu, Dongsheng, additional, Rushton, Moira Katherine, additional, Vera Badillo, Francisco Emilio, additional, Smoragiewicz, Martin, additional, and Wyatt, Alexander William, additional

Published
2020
Full Text
View/download PDF

17. The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial

Author

Bjarnason, Georg A., primary, Knox, Jennifer J., additional, Kollmannsberger, Christian K., additional, Soulieres, Denis, additional, Ernst, D. Scott, additional, Zalewski, Pawel, additional, Canil, Christina M., additional, Winquist, Eric, additional, Hotte, Sebastien J., additional, North, Scott A., additional, Heng, Daniel Yick Chin, additional, Macfarlane, Robyn Jane, additional, Venner, Peter M., additional, Kapoor, Anil, additional, Hansen, Aaron R., additional, Eigl, Bernhard J., additional, Czaykowski, Piotr, additional, Boyd, Ben, additional, Wang, Lisa, additional, and Basappa, Naveen S., additional

Published
2019
Full Text
View/download PDF

18. Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer.

Author

Bjarnason, Georg A., primary, Knox, Jennifer J., additional, Kollmannsberger, Christian K., additional, Soulieres, Denis, additional, Ernst, D. Scott, additional, Zalewski, Pawel, additional, Canil, Christina M., additional, Winquist, Eric, additional, Hotte, Sebastien J., additional, North, Scott A., additional, Heng, Daniel Yick Chin, additional, Macfarlane, Robyn Jane, additional, Venner, Peter M., additional, Kapoor, Anil, additional, Hansen, Aaron Richard, additional, Eigl, Bernhard J., additional, Czaykowski, Piotr, additional, Boyd, Ben, additional, Wang, Lisa, additional, and Basappa, Naveen S., additional

Published
2017
Full Text
View/download PDF

19. Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC).

Author

Bjarnason, Georg A., primary, Knox, Jennifer J., additional, Kollmannsberger, Christian K., additional, Soulieres, Denis, additional, Ernst, D. Scott, additional, Canil, Christina M., additional, Winquist, Eric, additional, Zalewski, Pawel, additional, Hotte, Sebastien J., additional, North, Scott A., additional, Heng, Daniel Yick Chin, additional, Macfarlane, Robyn Jane, additional, Venner, Peter M., additional, Tannock, Ian, additional, Kapoor, Anil, additional, Eigl, Bernhard J., additional, Hansen, Aaron Richard, additional, Czaykowski, Piotr, additional, Boyd, Ben, additional, and Basappa, Naveen S., additional

Published
2015
Full Text
View/download PDF

20. NCIC CTG IND.206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers.

Author

Dancey, Janet, primary, Krzyzanowska, Monika K., additional, Provencher, Diane M., additional, Cheung, Winson Y., additional, Macfarlane, Robyn Jane, additional, Alcindor, Thierry, additional, Ghatage, Prafull, additional, Gupta, Abha A., additional, Laurie, Scott Andrew, additional, Sawyer, Michael B., additional, Welch, Stephen, additional, Salim, Muhammad, additional, Ellard, Susan, additional, Wall, Donna Ann, additional, Tsao, Ming Sound, additional, Sederias, Joana, additional, Xu, Hao, additional, Nielsen, Torsten O., additional, Asa, Sylvia L., additional, and Hirte, Hal W., additional

Published
2015
Full Text
View/download PDF

21. IND 205B: A phase II study of the PI3K inhibitor PX-866 and continued abiraterone/prednisone in patients with recurrent or metastatic castration resistant prostate cancer (CRPC) with PSA progression on abiraterone/prednisone.

Author

Hotte, Sebastien J., primary, Joshua, Anthony M., additional, Torri, Vamsee, additional, Macfarlane, Robyn Jane, additional, Basappa, Naveen S., additional, Powers, Jean, additional, Winquist, Eric, additional, Mukherjee, Som, additional, Gregg, Richard William, additional, Kollmannsberger, Christian K., additional, Finch, Daygen L., additional, Xu, Hao, additional, Hausman, Diana Felice, additional, Seymour, Lesley, additional, Eisenhauer, Elizabeth A., additional, and Chi, Kim N., additional

Published
2015
Full Text
View/download PDF

22. A phase II multicenter study of the efficacy and safety of sunitinib given on an individualized schedule as first-line therapy for metastatic renal cell cancer.

Author

Bjarnason, Georg A., primary, Basappa, Naveen S., additional, Knox, Jennifer J., additional, Kollmannsberger, Christian K., additional, Reaume, M. Neil Neil, additional, Zalewski, Pawel, additional, Macfarlane, Robyn Jane, additional, MacKenzie, Mary J., additional, Hotte, Sebastien J., additional, Heng, Daniel Yick Chin, additional, Soulieres, Denis, additional, and Miller, Jessie, additional

Published
2013
Full Text
View/download PDF

28. Lapatinib for breast cancer: a review of the current literature

Author

MacFarlane, Robyn J and Gelmon, Karen A

Abstract

Importance of the field:The identification of HER-2 expression as a predictive and prognostic marker revolutionized breast cancer. Trastuzumab, a humanized mAb, improves survival in both early and advanced HER-2 overexpressing breast cancer. However, many cancers either do not respond or develop resistance to this agent. Lapatinib is an oral tyrosine kinase inhibitor which has both HER-1 and -2 activities and has been licensed for use in recurrent breast cancer that overexpresses HER-2. Studies of lapatinib in early breast cancer are ongoing.Areas covered in this review:A PubMed search was conducted using ‘lapatinib’ and ‘breast cancer’ as the key words. All published works up to July 2010 were reviewed. A manual review of abstracts presented at the ASCO Annual meeting and the San Antonio Breast Cancer Symposium was conducted for the last 2 years. In this review, we summarize the current knowledge of lapatinib and pose questions which need to be addressed as we further expand our knowledge of the HER-2 subtypes of breast cancer.What the reader will gain:The reader will gain an up-to-date and comprehensive review of the current literature as it pertains to the safety and efficacy of lapatinib in the treatment of breast cancer.Take home message:Lapatinib has provided an alternative for the treatment of advanced HER-2 overexpressing breast cancer and is currently being assessed in early disease.

Published
2011
Full Text
View/download PDF

29. Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer

Author

Watahiki, Akira, Macfarlane, Robyn J., Gleave, Martin E., Crea, Francesco, Wang, Yuzhuo, Helgason, Cheryl D., and Chi, Kim N.

Subjects
3. Good health
Abstract

MicroRNAs (miRNAs) have emerged as key regulators of numerous biological processes, and increasing evidence suggests that circulating miRNAs may be useful biomarkers of clinical disease. In this study, we sought to identify plasma miRNAs that differentiate patients with metastatic castration resistant prostate cancer (mCRPC) from those with localized prostate cancer (PCa). Pooled plasma samples from patients with localized PCa or mCRPC (25 per group) were assayed using the Exiqon miRNA qPCR panel, and the differential expression of selected candidates was validated using qRT-PCR. We identified 63 miRNAs upregulated in mCRPC versus localized PCa, while only four were downregulated. Pearson’s correlation analysis revealed two highly correlated groups: one consisting of miR-141, miR375 and miR-200c and the other including miR151-3p, miR423-3p, miR-126, miR152 and miR-21. A third group, containing miR-16 and miR-205, showed less correlation. One miRNA from each group (miR-141, miR151-3p and miR-16) was used for logistic regression analysis and proved to increase the sensitivity of the prostate-specific antigen (PSA) test alone. While no miRNA alone differentiated localized PCa and mCRPC, combinations had greater sensitivity and specificity. The expression of these 10 candidates was assayed for association with clinical parameters of disease progression through the cBio portal. Our results demonstrate that plasma levels of selected miRNAs are potential biomarkers to differentiate localized PCa and mCRPC.

30. Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease

Author

Scott L. Townley, Krisna Murti, Joanna L. Gillis, Luke A. Selth, Lisa M. Butler, Kim N. Chi, Wayne D. Tilley, Robyn Jane Macfarlane, Villis R. Marshall, Aleksandra M. Ochnik, Selth, Luke A, Townley, Scott, Gillis, Joanna L, Ochnik, Aleksandra M, Murti, Krisna, Macfarlane, Robyn J, Chi, Kim N, Marshall, Villis R, Tilley, Wayne D, and Butler, Lisa M

Subjects
PCA3, Male, Cancer Research, mouse model, Mice, Transgenic, Prostate cancer, Mice, Prostate, microRNA, medicine, Biomarkers, Tumor, Animals, Humans, Oligonucleotide Array Sequence Analysis, business.industry, Gene Expression Profiling, Cancer, Prostatic Neoplasms, prostate cancer, medicine.disease, Prognosis, Mice, Inbred C57BL, MicroRNAs, medicine.anatomical_structure, Oncology, Immunology, Cancer research, biomarker, Biomarker (medicine), Adenocarcinoma, business, serum, Tramp
Abstract

Circulating microRNAs (miRNAs) are emerging as useful non-invasive markers of disease. The objective of this study was to use a mouse model of prostate cancer as a tool to discover serum miRNAs that could be assessed in a clinical setting. Global miRNA profiling identified 46 miRNAs at significantly altered levels (p ≤ 0.05) in the serum of TRansgenic Adenocarcinoma of Mouse Prostate (TRAMP) mice with advanced prostate cancer compared to healthy controls. A subset of these miRNAs with known human homologues were validated in an independent cohort of mice and then measured in serum from men with metastatic castration-resistant prostate cancer (mCRPC; n = 25) or healthy men (n = 25). Four miRNAs altered in mice, mmu-miR-141, mmu-miR-298, mmu-miR-346 and mmu-miR-375, were also found to be at differential levels in the serum of men with mCRPC. Three of these (hsa-miR-141, hsa-miR-298 and hsa-miR-375) were upregulated in prostate tumors compared with normal prostate tissue, suggesting that they are released into the blood as disease progresses. Moreover, the intra-tumoral expression of hsa-miR-141 and hsa-miR-375 were predictors of biochemical relapse after surgery. This study is the first to demonstrate that specific serum miRNAs are common between human prostate cancer and a mouse model of the disease, highlighting the potential of such models for the discovery of novel biomarkers. Refereed/Peer-reviewed

Published
2011

31. Using quality improvement frameworks to develop, implement, and evaluate a novel ambulatory oncology pharmacy practice model: A descriptive example.

Author

Underhill H, Leblanc M, Macfarlane R, and Hutton L

Abstract

Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time., Purpose: To describe the application of the Plan-Do-Study-Act quality improvement framework in the development, implementation, and evaluation of a novel pharmacy practice model in ambulatory oncology., Summary: Four iterations of the Plan-Do-Study-Act framework were completed to develop a patient-facing, pharmacist-led ambulatory oncology clinic program. The clinic provided care to patients with prostate cancer on oral anticancer therapy. Metrics were collected throughout all stages of development to inform target processes for improvement. The pharmacist saw 136 patients between July 2019 and January 2023, resulting in 464 total encounters. The pharmacist provided clinical interventions and counseling to patients newly starting on oral anticancer therapy and those established on therapy using a longitudinal model of care., Conclusion: Application of the Plan-Do-Study-Act quality improvement framework to a novel pharmacy practice model supported the development, evaluation, and sustainability of a pharmacist-led ambulatory oncology clinic providing care to patients with prostate cancer on oral anticancer therapy., (© American Society of Health-System Pharmacists 2024. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results